IS5200A - Pýrazólópýrimídínón sem letja tegund 5 sýklískan gúanósín 3', 5' - mónófosfat fosfódíesterasa (cGMPPDE5) til meðhöndlunar á kynferðistruflunum - Google Patents

Pýrazólópýrimídínón sem letja tegund 5 sýklískan gúanósín 3', 5' - mónófosfat fosfódíesterasa (cGMPPDE5) til meðhöndlunar á kynferðistruflunum

Info

Publication number: IS5200A
Authority: IS; Iceland
Prior art keywords: cgmppde5; pyrazolopyrimidinone; treatment; cyclic guanosine; sexual disorders
Prior art date: 1997-04-25

Application number

IS5200A

Other languages

English (en)

Inventor

Edward Bunnage Mark

Paul Mathias John

Derek Albert Street Stephen

Wood Anthony

Original Assignee

Pfizer Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-04-25

Filing date

1999-09-28

Publication date

1999-09-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27268823&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS5200(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-04-25 Priority claimed from GBGB9708406.5A external-priority patent/GB9708406D0/en

1997-07-22 Priority claimed from GB9715380A external-priority patent/GB9715380D0/en

1997-10-30 Priority claimed from GBGB9722954.6A external-priority patent/GB9722954D0/en

1999-09-28 Application filed by Pfizer Inc. filed Critical Pfizer Inc.

1999-09-28 Publication of IS5200A publication Critical patent/IS5200A/is

Links

ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 title 1
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 title 1
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 title 1
DOTPSQVYOBAWPQ-UHFFFAOYSA-N pyrazolo[4,3-d]pyrimidin-3-one Chemical compound N1=CN=C2C(=O)N=NC2=C1 DOTPSQVYOBAWPQ-UHFFFAOYSA-N 0.000 title 1
208000012201 sexual and gender identity disease Diseases 0.000 title 1
208000015891 sexual disease Diseases 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pulmonology (AREA)
Ophthalmology & Optometry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Immunology (AREA)
Reproductive Health (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Otolaryngology (AREA)
Gynecology & Obstetrics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)

IS5200A 1997-04-25 1999-09-28 Pýrazólópýrimídínón sem letja tegund 5 sýklískan gúanósín 3', 5' - mónófosfat fosfódíesterasa (cGMPPDE5) til meðhöndlunar á kynferðistruflunum IS5200A (is)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GBGB9708406.5A GB9708406D0 (en)	1997-04-25	1997-04-25	Therapeutic agents
GB9715380A GB9715380D0 (en)	1997-07-22	1997-07-22	Therapeutic agents
GBGB9722954.6A GB9722954D0 (en)	1997-10-30	1997-10-30	Therapeutic agents
PCT/EP1998/002257 WO1998049166A1 (en)	1997-04-25	1998-04-10	PYRAZOLOPYRIMIDINONES WHICH INHIBIT TYPE 5 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (cGMP PDE5) FOR THE TREATMENT OF SEXUAL DYSFUNCTION

Publications (1)

Publication Number	Publication Date
IS5200A true IS5200A (is)	1999-09-28

Family

ID=27268823

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS5200A IS5200A (is)	1997-04-25	1999-09-28	Pýrazólópýrimídínón sem letja tegund 5 sýklískan gúanósín 3', 5' - mónófosfat fosfódíesterasa (cGMPPDE5) til meðhöndlunar á kynferðistruflunum

Country Status (31)

Country	Link
US (2)	US6723719B1 (is)
EP (1)	EP0977756A1 (is)
JP (2)	JP3563078B2 (is)
KR (2)	KR100441229B1 (is)
CN (2)	CN1188415C (is)
AP (1)	AP1002A (is)
AR (1)	AR015595A1 (is)
AU (1)	AU730670B2 (is)
BG (1)	BG103828A (is)
BR (1)	BR9810233A (is)
CA (1)	CA2288910C (is)
CO (1)	CO4940472A1 (is)
CZ (1)	CZ299633B6 (is)
DZ (1)	DZ2465A1 (is)
EA (2)	EA002057B1 (is)
HR (1)	HRP980222B1 (is)
ID (1)	ID22834A (is)
IL (5)	IL132276A0 (is)
IS (1)	IS5200A (is)
MA (1)	MA24529A1 (is)
NO (1)	NO314585B1 (is)
NZ (1)	NZ338075A (is)
OA (1)	OA11168A (is)
PA (1)	PA8450401A1 (is)
PE (1)	PE68699A1 (is)
PL (1)	PL336586A1 (is)
RS (1)	RS50118B (is)
SK (1)	SK285991B6 (is)
TN (1)	TNSN98053A1 (is)
TR (1)	TR199902646T2 (is)
WO (1)	WO1998049166A1 (is)

Families Citing this family (142)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9423910D0 (en) *	1994-11-26	1995-01-11	Pfizer Ltd	Therapeutic agents
IL120266A (en)	1996-02-28	2005-05-17	Pfizer	Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
GB9612514D0 (en) *	1996-06-14	1996-08-14	Pfizer Ltd	Novel process
US6331543B1 (en)	1996-11-01	2001-12-18	Nitromed, Inc.	Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
SK285991B6 (sk)	1997-04-25	2008-01-07	Pfizer Inc.	Pyrazolopyrimidinóny, spôsob a medziprodukty na ich výrobu, ich použitie a farmaceutické a veterinárne kompozície na ich báze
GB9722520D0 (en)	1997-10-24	1997-12-24	Pfizer Ltd	Compounds
EP1371647B1 (en) *	1998-04-20	2005-07-13	Pfizer Inc.	Pyridine-3-carboxylic acid derivatives and their use as intermediates
DE19827640A1 (de)	1998-06-20	1999-12-23	Bayer Ag	7-Alkyl- und Cycloalkyl-substituierte Imidazotriazinone
GB9822238D0 (en) *	1998-10-12	1998-12-09	Pfizer Ltd	Process for preparation of pyrazolo[4,3-D]pyrimidin-7-ones and intermediates thereof
GB9823102D0 (en)	1998-10-23	1998-12-16	Pfizer Ltd	Pharmaceutically active compounds
GB9823103D0 (en)	1998-10-23	1998-12-16	Pfizer Ltd	Pharmaceutically active compounds
GB9823101D0 (en)	1998-10-23	1998-12-16	Pfizer Ltd	Pharmaceutically active compounds
KR100353014B1 (ko) *	1998-11-11	2002-09-18	동아제약 주식회사	발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
RU2220145C2 (ru) *	1998-11-11	2003-12-27	Донг А Фарм. Ко., Лтд.	Производные пиразолопиримидинона для лечения импотенции и способ их получения
US6225315B1 (en)	1998-11-30	2001-05-01	Pfizer Inc	Method of treating nitrate-induced tolerance
NO20002097L (no) *	1999-04-30	2001-10-26	Lilly Icos Llc	Fremstillingsgjenstander
CA2365782A1 (en) *	1999-04-30	2000-11-09	William E. Pullman	Treatment of female arousal disorder
JP3145364B2 (ja)	1999-06-04	2001-03-12	ザ・ヨルダニアン・フアーマシユーテイカル・エム・エフ・ジー・アンド・メデイカル・イクイツプメント・カンパニー・リミテツド	新規化合物及び該化合物を含有する医薬組成物
ATE228134T1 (de) *	1999-06-04	2002-12-15	Jordanian Pharmaceutical Mfg A	Kondensierte pyrimidinderivate und diese enthaltende pharmazeutische zubereitungen
ES2166270B1 (es) *	1999-07-27	2003-04-01	Almirall Prodesfarma Sa	Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona.
DE19942474A1 (de) *	1999-09-06	2001-03-15	Merck Patent Gmbh	Pyrazolo[4,3-d]pyrimidine
EP1222190A1 (en)	1999-10-11	2002-07-17	Pfizer Limited	5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dihydropyrazolo[4,3-d]pyrimidin-7-ones as phosphodiesterase inhibitors
GB9923968D0 (en) *	1999-10-11	1999-12-15	Pfizer Ltd	Therapeutic agents
US6350751B1 (en)	1999-10-11	2002-02-26	Pfizer Inc.	Therapeutic agents
TWI265925B (en) *	1999-10-11	2006-11-11	Pfizer	Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
YU59100A (sh) *	1999-10-11	2003-10-31	Pfizer Inc.	Postupak za dobijanje pirazolo (4,3-d) pirimidin-7-ona-3-piridilsulfonil jedinjenja i njihova intermedijera
TW200400821A (en) *	1999-11-02	2004-01-16	Pfizer	Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient
WO2001047928A2 (de) *	1999-12-24	2001-07-05	Bayer Aktiengesellschaft	Imidazo 1,3,5 triazinone und ihre verwendung
CA2395410A1 (en) *	1999-12-24	2001-07-05	Bayer Aktiengesellschaft	Triazolotriazinones and the use thereof
KR100358083B1 (ko) *	2000-02-17	2002-10-25	에스케이케미칼주식회사	피롤로피리미디논 유도체와 이의 제조방법, 그리고 이의용도
WO2001087888A1 (en) *	2000-05-17	2001-11-22	Sk Chemicals Co., Ltd.	Pyrazolopyrimidinone derivatives, process for their preparation and their use
KR100377782B1 (ko) *	2000-06-23	2003-03-29	동아제약 주식회사	발기부전 치료에 효과를 갖는 피라졸로피리미디논화합물의 제조방법
US6407259B1 (en)	2000-07-28	2002-06-18	Pfizer Inc.	Process for the preparation of pyrazoles
EP1176142A1 (en) *	2000-07-28	2002-01-30	Pfizer Inc.	Process for the preparation of pyrazoles
AU2001276607A1 (en) *	2000-08-11	2002-02-25	Pfizer Inc.	Treatment of the insulin resistance syndrome with selective CGMP PDE5 inhibitors
PE20020394A1 (es)	2000-08-18	2002-06-21	Agouron Pharma	Compuestos de pirazol y composiciones farmaceuticas que los contienen, que modulan y/o inhiben la actividad de erab/hadh2
WO2002016364A1 (en) *	2000-08-23	2002-02-28	Lg Life Sciences Ltd.	Polyethoxylated pyrazolo pyrimidinone derivatives, process for preparation thereof and pharmaceutical compositions comprising the same for the treatment of impotence
US6821978B2 (en)	2000-09-19	2004-11-23	Schering Corporation	Xanthine phosphodiesterase V inhibitors
GB0025782D0 (en) *	2000-10-20	2000-12-06	Pfizer Ltd	Use of inhibitors
US6548508B2 (en)	2000-10-20	2003-04-15	Pfizer, Inc.	Use of PDE V inhibitors for improved fecundity in mammals
SE0004780D0 (sv)	2000-12-22	2000-12-22	Jordanian Pharmaceutical Mfg &	Novel compunds
WO2003042216A1 (en)	2001-11-09	2003-05-22	Schering Corporation	Polycyclic guanine derivative phosphodiesterase v inhibitors
GB0129274D0 (en) *	2001-12-06	2002-01-23	Pfizer Ltd	Novel kit
ATE478872T1 (de)	2002-03-28	2010-09-15	Ustav Ex Botan Av Cr V V I I O	Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung
GB0219961D0 (en)	2002-08-28	2002-10-02	Pfizer Ltd	Oxytocin inhibitors
US7323462B2 (en)	2002-12-10	2008-01-29	Pfizer Inc.	Morpholine dopamine agonists
DE60332387D1 (de)	2002-12-13	2010-06-10	Warner Lambert Co	Alpha-2-delta-ligand zur behandlung vonsymptomen der unteren harnwege
EA008596B1 (ru)	2003-04-29	2007-06-29	Пфайзер Инк.	5,7-ДИАМИНОПИРАЗОЛО[4,3-d]ПИРИМИДИНЫ, ПОЛЕЗНЫЕ ПРИ ЛЕЧЕНИИ ГИПЕРТЕНЗИИ
WO2005012256A1 (en)	2003-07-22	2005-02-10	Astex Therapeutics Limited	3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
US7291640B2 (en)	2003-09-22	2007-11-06	Pfizer Inc.	Substituted triazole derivatives as oxytocin antagonists
US7572799B2 (en)	2003-11-24	2009-08-11	Pfizer Inc	Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
EP1779852A3 (en) *	2004-01-05	2007-05-09	Teva Pharmaceutical Industries Ltd.	Processes for the production of sildenafil base and citrate salt
US7618976B2 (en)	2004-01-05	2009-11-17	Teva Pharmaceutical Industries Ltd	Methods for the production of sildenafil base and citrate salt
JP2007518788A (ja)	2004-01-22	2007-07-12	ファイザー・インク	バソプレッシンのアンタゴニスト活性を阻害するトリアゾール誘導体
US7649002B2 (en)	2004-02-04	2010-01-19	Pfizer Inc	(3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
DK1742950T3 (da)	2004-04-07	2009-03-16	Pfizer Ltd	Pyrazolo-[4,3-D]-pyrimidiner
US7897607B2 (en) *	2004-04-07	2011-03-01	Takeda Pharmaceutical Company Limited	Cyclic compounds
CA2577442A1 (en)	2004-08-17	2006-03-02	The Johns Hopkins University	Pde5 inhibitor compositions and methods for treating cardiac indications
TWI367098B (en) *	2004-12-23	2012-07-01	Kowa Co	Treating agent for glaucoma
US8404718B2 (en)	2005-01-21	2013-03-26	Astex Therapeutics Limited	Combinations of pyrazole kinase inhibitors
AR054425A1 (es)	2005-01-21	2007-06-27	Astex Therapeutics Ltd	Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
ES2313626T3 (es)	2005-03-21	2009-03-01	Pfizer Limited	Derivados de triazol sustituidos como antagonistas de oxitocina.
BRPI0610498A2 (pt)	2005-04-19	2010-06-22	Nycomed Gmbh	uso de roflumilast,composição farmacêutica, produto de combinação e kit para o tratamento de hipertensão pulmonar
US8506934B2 (en)	2005-04-29	2013-08-13	Robert I. Henkin	Methods for detection of biological substances
CA2608018C (en)	2005-05-12	2010-07-13	Pfizer Inc.	Anhydrous crystalline forms of n-[1-(2-ethoxyethyl)-5-(n-ethyl-n-methylamino)-7-(4-methylpyridin-2-yl-amino)-1h-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide
ZA200804550B (en)	2005-11-09	2009-08-26	Combinatorx Inc	Methods, compositions, and kits for the treatment of medical conditions
JP2007169278A (ja) *	2005-12-20	2007-07-05	Pfizer Prod Inc	Ｌｕｔｓ処置用の医薬組合せ
GB0601951D0 (en)	2006-01-31	2006-03-15	Novartis Ag	Organic compounds
WO2008095136A2 (en)	2007-01-31	2008-08-07	Henkin Robert I	Methods for detection of biological substances
US8580801B2 (en)	2008-07-23	2013-11-12	Robert I. Henkin	Phosphodiesterase inhibitor treatment
CN101747282A (zh)	2008-12-10	2010-06-23	上海特化医药科技有限公司	一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途
JP2012513464A (ja)	2008-12-23	2012-06-14	ザトラスティーズオブコロンビアユニヴァーシティインザシティオブニューヨーク	ホスホジエステラーゼ阻害剤及びその使用
GB0903493D0 (en)	2009-02-27	2009-04-08	Vantia Ltd	New compounds
TWI462739B (zh)	2010-11-02	2014-12-01	Univ Kaohsiung Medical	Ｓｉｌｄｅｎａｆｉｌ－同族物四級銨哌嗪鹽類之製備及醫療用途
US8815271B2 (en)	2010-11-03	2014-08-26	Dow Agrosciences, Llc.	Pesticidal compositions and processes related thereto
CN102134242B (zh) *	2011-01-21	2013-08-28	浙江大德药业集团有限公司	一种用于治疗阳痿的快速长效的化合物
JP2014526461A (ja) *	2011-09-09	2014-10-06	エスケーケミカルズカンパニー，リミテッド	Ｐｄｅ５抑制剤を含む皮膚しわ改善用組成物
US8937083B2 (en)	2011-10-26	2015-01-20	DowAgroSciences, LLC	Pesticidal compositions and processes related thereto
WO2013067309A1 (en)	2011-11-04	2013-05-10	Xion Pharmaceutical Corporation	Methods and compositions for oral administration of melanocortin receptor agonist compounds
EP2804603A1 (en)	2012-01-10	2014-11-26	President and Fellows of Harvard College	Beta-cell replication promoting compounds and methods of their use
WO2013109738A1 (en)	2012-01-17	2013-07-25	The Trustees Of Columbia University In The City Of New York	Novel phosphodiesterase inhibitors and uses thereof
US9708288B2 (en)	2012-04-27	2017-07-18	Dow Agrosciences Llc	Pesticidal compositions and processes related thereto
US9282739B2 (en)	2012-04-27	2016-03-15	Dow Agrosciences Llc	Pesticidal compositions and processes related thereto
RU2627654C2 (ru)	2012-04-27	2017-08-09	ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи	Пестицидные композиции и относящиеся к ним способы
WO2014055801A1 (en)	2012-10-05	2014-04-10	Henkin Robert I	Phosphodiesterase inhibitors for treating taste and smell disorders
ES2882258T3 (es)	2012-12-21	2021-12-01	Mayo Found Medical Education & Res	Métodos y materiales para tratar estenosis de la válvula aórtica calcificada
CN103265479B (zh) *	2013-06-14	2017-12-08	南开大学	一种6‑氯甲基烟酸叔丁酯的合成方法
WO2015009930A2 (en)	2013-07-17	2015-01-22	The Trustees Of Columbia University In The City Of New York	Novel phosphodiesterase inhibitors and uses thereof
EP3057430A4 (en)	2013-10-17	2017-09-13	Dow AgroSciences LLC	Processes for the preparation of pesticidal compounds
CN105636440A (zh)	2013-10-17	2016-06-01	美国陶氏益农公司	制备杀虫化合物的方法
CN105636446B (zh)	2013-10-17	2018-07-13	美国陶氏益农公司	制备杀虫化合物的方法
KR20160075565A (ko)	2013-10-17	2016-06-29	다우 아그로사이언시즈 엘엘씨	살충성 화합물의 제조 방법
BR112016008070B8 (pt)	2013-10-17	2022-08-23	Dow Agrosciences Llc	Compostos pesticidas, e seus processos de preparação
JP2016535010A (ja)	2013-10-17	2016-11-10	ダウアグロサイエンシィズエルエルシー	有害生物防除性化合物の製造方法
EP3057426A4 (en)	2013-10-17	2017-03-29	Dow AgroSciences LLC	Processes for the preparation of pesticidal compounds
AR098101A1 (es)	2013-10-22	2016-05-04	Dow Agrosciences Llc	Composiciones plaguicidas y métodos relacionados
AR098094A1 (es)	2013-10-22	2016-05-04	Dow Agrosciences Llc	Composiciones plaguicidas sinérgicas y métodos relacionados
EP3060044A4 (en)	2013-10-22	2017-04-05	Dow AgroSciences LLC	Synergistic pesticidal compositions and related methods
CN105828608A (zh)	2013-10-22	2016-08-03	美国陶氏益农公司	杀虫组合物和与其相关的方法
MX2016005319A (es)	2013-10-22	2016-08-12	Dow Agrosciences Llc	Composiciones pesticidas y metodos relacionados.
EP3060054A4 (en)	2013-10-22	2017-04-05	Dow AgroSciences LLC	Synergistic pesticidal compositions and related methods
US9497966B2 (en)	2013-10-22	2016-11-22	Dow Agrosciences Llc	Pesticidal compositions and related methods
CN105792652A (zh)	2013-10-22	2016-07-20	美国陶氏益农公司	协同杀虫组合物和相关方法
US9137998B2 (en)	2013-10-22	2015-09-22	Dow Agrosciences Llc	Pesticidal compositions and related methods
WO2015061140A1 (en)	2013-10-22	2015-04-30	Dow Agrosciences Llc	Synergistic pesticidal compositions and related methods
JP2016538265A (ja)	2013-10-22	2016-12-08	ダウアグロサイエンシィズエルエルシー	相乗的有害生物防除組成物および関連する方法
CA2927226A1 (en)	2013-10-22	2015-04-30	Dow Agrosciences Llc	Synergistic pesticidal compositions and related methods
RU2658995C2 (ru)	2013-10-22	2018-06-26	ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи	Пестицидные композиции и связанные с ними способы
CA2927206A1 (en)	2013-10-22	2015-04-30	Dow Agrosciences Llc	Synergistic pesticidal compositions and related methods
US9155304B2 (en)	2013-10-22	2015-10-13	Dow Agrosciences Llc	Synergistic pesticidal compositions and related methods
AR098091A1 (es)	2013-10-22	2016-05-04	Dow Agrosciences Llc	Composiciones pesticidas sinérgicas y métodos relacionados
CN105792650A (zh)	2013-10-22	2016-07-20	美国陶氏益农公司	协同杀虫组合物和相关方法
US10598672B2 (en)	2014-02-18	2020-03-24	Cyrano Therapeutics, Inc.	Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
EP3174856A4 (en)	2014-07-31	2018-01-10	Dow AgroSciences LLC	Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine
EP3186229A4 (en)	2014-07-31	2018-01-10	Dow AgroSciences LLC	Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine
US9249122B1 (en)	2014-07-31	2016-02-02	Dow Agrosciences Llc	Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine
WO2016028328A1 (en)	2014-08-19	2016-02-25	Dow Agrosciences Llc	Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine
JP2017528469A (ja)	2014-09-12	2017-09-28	ダウアグロサイエンシィズエルエルシー	３−（３−クロロ−１ｈ−ピラゾール−１−イル）ピリジンの調製方法
IL292225B2 (en) *	2014-09-17	2024-12-01	Intra Cellular Therapies Inc	Derivatives of 5,7,7-trimethyl-[2H]-imidazo-[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one and pharmaceutical compositions comprising them.
WO2016145614A1 (en)	2015-03-17	2016-09-22	Merck Sharp & Dohme Corp.	Triazolyl pyrimidinone compounds as pde2 inhibitors
WO2016183741A1 (en)	2015-05-15	2016-11-24	Merck Sharp & Dohme Corp.	Pyrimidinone amide compounds as pde2 inhibitors
US20180072718A1 (en)	2016-09-09	2018-03-15	Incyte Corporation	Pyrazolopyridine compounds and uses thereof
IL292977A (en)	2016-09-09	2022-07-01	Incyte Corp	Pyrazolopyridine derivatives as modulators of hpk1 and their use in cancer therapy
AR109595A1 (es)	2016-09-09	2018-12-26	Incyte Corp	Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1
US10100033B2 (en)	2016-12-29	2018-10-16	Dow Agrosciences Llc	Processes for the preparation of pesticidal compounds
WO2018125817A1 (en)	2016-12-29	2018-07-05	Dow Agrosciences Llc	Processes for the preparation of pesticidal compounds
WO2018152220A1 (en)	2017-02-15	2018-08-23	Incyte Corporation	Pyrazolopyridine compounds and uses thereof
US10722495B2 (en)	2017-09-08	2020-07-28	Incyte Corporation	Cyanoindazole compounds and uses thereof
US10752635B2 (en)	2018-02-20	2020-08-25	Incyte Corporation	Indazole compounds and uses thereof
US10745388B2 (en)	2018-02-20	2020-08-18	Incyte Corporation	Indazole compounds and uses thereof
JP7526673B2 (ja)	2018-02-20	2024-08-01	インサイト・コーポレイション	がんを治療するためのｈｐｋ１阻害剤としてのｎ－（フェニル）－２－（フェニル）ピリミジン－４－カルボキサミド誘導体及び関連化合物
US11299473B2 (en)	2018-04-13	2022-04-12	Incyte Corporation	Benzimidazole and indole compounds and uses thereof
US10899755B2 (en)	2018-08-08	2021-01-26	Incyte Corporation	Benzothiazole compounds and uses thereof
ES2973117T3 (es)	2018-09-25	2024-06-18	Incyte Corp	Compuestos de pirazolo[4,3-d]pirimidina como moduladores de ALK2 y/o FGFR
EP3887376A1 (en) *	2018-11-28	2021-10-06	Topadur Pharma AG	Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
MX2021012409A (es)	2019-04-10	2021-11-12	Mayo Found Medical Education & Res	Metodos y materiales para el tratamiento dependiente del genero de la disfuncion cardiovascular.
KR20220059480A (ko)	2019-08-06	2022-05-10	인사이트 코포레이션	고체 형태의 hpk1 억제제
WO2021194893A1 (en)	2020-03-24	2021-09-30	Cyrano Therapeutics, Inc.	Treatment of chemosensory dysfunction from a coronavirus infection
CN113493459B (zh) *	2020-04-07	2022-12-13	广州白云山医药集团股份有限公司白云山制药总厂	Pde5抑制剂化合物及其制备方法和应用
CN113754612B (zh) *	2021-10-26	2023-09-26	山东安舜制药有限公司	一种西地那非中间体的制备方法
CN115785101B (zh) *	2022-11-23	2023-10-13	西安市食品药品检验所	一种含有苯基哌嗪结构的那非类化合物及其制备方法
CN116332856A (zh) *	2023-01-04	2023-06-27	荟达医药科技(上海)有限公司	一种4-哒嗪甲醇的合成方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3992441A (en)	1972-12-26	1976-11-16	Pfizer Inc.	Sulfamylbenzoic acids
DE3420985A1 (de)	1983-10-15	1985-04-25	Bayer Ag, 5090 Leverkusen	Substituierte 5-acylamino-1-phenylpyrazole
US4871843A (en)	1983-10-18	1989-10-03	Dropic-Societe Civile De Gestion De Droits De Propriete Industrielle	Cyclic benzenesulfonamides, process for their preparation and their use as active substance of pharmaceutical compositions
US4663326A (en)	1985-04-04	1987-05-05	Warner-Lambert Company	Pyrazolo[4,3-d]pyrimidine-5,7-(4H,6H)dione or -5-thione-7-one analogs
US4666908A (en)	1985-04-05	1987-05-19	Warner-Lambert Company	5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
US5075310A (en)	1988-07-01	1991-12-24	Smith Kline & French Laboratories, Ltd.	Pyrimidone derivatives as bronchodilators
GB8817651D0 (en) *	1988-07-25	1988-09-01	Smith Kline French Lab	Chemical compounds
GB8827988D0 (en)	1988-11-30	1989-01-05	Smith Kline French Lab	Chemical compounds
GB8928346D0 (en)	1989-12-15	1990-02-21	Smith Kline French Lab	Chemical compounds
US5250534A (en)	1990-06-20	1993-10-05	Pfizer Inc.	Pyrazolopyrimidinone antianginal agents
GB9013750D0 (en)	1990-06-20	1990-08-08	Pfizer Ltd	Therapeutic agents
GB9114760D0 (en)	1991-07-09	1991-08-28	Pfizer Ltd	Therapeutic agents
GB9119704D0 (en)	1991-09-14	1991-10-30	Pfizer Ltd	Therapeutic agents
GB9121028D0 (en)	1991-10-03	1991-11-13	Pfizer Ltd	Therapeutic agents
GB9126260D0 (en)	1991-12-11	1992-02-12	Pfizer Ltd	Therapeutic agents
GB9202238D0 (en)	1992-02-03	1992-03-18	Wellcome Found	Compounds
US5294612A (en)	1992-03-30	1994-03-15	Sterling Winthrop Inc.	6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
US5734053A (en)	1992-06-26	1998-03-31	Pfizer Inc	Purinone antianginal agents
GB9213623D0 (en)	1992-06-26	1992-08-12	Pfizer Ltd	Therapeutic agents
JP2657760B2 (ja)	1992-07-15	1997-09-24	小野薬品工業株式会社	４−アミノキナゾリン誘導体およびそれを含有する医薬品
GB9218322D0 (en)	1992-08-28	1992-10-14	Pfizer Ltd	Therapeutic agents
GB9301192D0 (en) *	1993-06-09	1993-06-09	Trott Francis W	Flower shaped mechanised table
GB9315017D0 (en)	1993-07-20	1993-09-01	Glaxo Lab Sa	Chemical compounds
GB9423910D0 (en)	1994-11-26	1995-01-11	Pfizer Ltd	Therapeutic agents
GB9423911D0 (en)	1994-11-26	1995-01-11	Pfizer Ltd	Therapeutic agents
US5656629A (en)	1995-03-10	1997-08-12	Sanofi Winthrop, Inc.	6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
HUP9801394A3 (en)	1995-03-10	2000-07-28	Sanofi Pharmaceuticals Inc New	6-phenyl-pyrazolo[3,4-d]pyrimidin-4-one derivatives and pharmaceutical compositions containing them
GB9612514D0 (en)	1996-06-14	1996-08-14	Pfizer Ltd	Novel process
SK285991B6 (sk)	1997-04-25	2008-01-07	Pfizer Inc.	Pyrazolopyrimidinóny, spôsob a medziprodukty na ich výrobu, ich použitie a farmaceutické a veterinárne kompozície na ich báze
EP1371647B1 (en)	1998-04-20	2005-07-13	Pfizer Inc.	Pyridine-3-carboxylic acid derivatives and their use as intermediates
US6087368A (en)	1998-06-08	2000-07-11	Bristol-Myers Squibb Company	Quinazolinone inhibitors of cGMP phosphodiesterase

1998
- 1998-04-10 SK SK1446-99A patent/SK285991B6/sk not_active IP Right Cessation
- 1998-04-10 RS YUP-524/99A patent/RS50118B/sr unknown
- 1998-04-10 JP JP54654398A patent/JP3563078B2/ja not_active Expired - Fee Related
- 1998-04-10 ID IDW991261A patent/ID22834A/id unknown
- 1998-04-10 NZ NZ338075A patent/NZ338075A/xx unknown
- 1998-04-10 PL PL98336586A patent/PL336586A1/xx not_active IP Right Cessation
- 1998-04-10 EA EA199900866A patent/EA002057B1/ru not_active IP Right Cessation
- 1998-04-10 CN CNB988044765A patent/CN1188415C/zh not_active Expired - Fee Related
- 1998-04-10 EA EA200100504A patent/EA004315B1/ru not_active IP Right Cessation
- 1998-04-10 WO PCT/EP1998/002257 patent/WO1998049166A1/en not_active Ceased
- 1998-04-10 CA CA002288910A patent/CA2288910C/en not_active Expired - Fee Related
- 1998-04-10 EP EP98924132A patent/EP0977756A1/en not_active Withdrawn
- 1998-04-10 KR KR10-1999-7009887A patent/KR100441229B1/ko not_active Expired - Fee Related
- 1998-04-10 TR TR1999/02646T patent/TR199902646T2/xx unknown
- 1998-04-10 CN CNB2004100685255A patent/CN1281588C/zh not_active Expired - Fee Related
- 1998-04-10 AU AU76445/98A patent/AU730670B2/en not_active Ceased
- 1998-04-10 KR KR10-2002-7006773A patent/KR100390612B1/ko not_active Expired - Fee Related
- 1998-04-10 BR BR9810233-8A patent/BR9810233A/pt active Search and Examination
- 1998-04-10 US US09/402,229 patent/US6723719B1/en not_active Expired - Fee Related
- 1998-04-10 IL IL13227698A patent/IL132276A0/xx active IP Right Grant
- 1998-04-10 CZ CZ0376799A patent/CZ299633B6/cs not_active IP Right Cessation
- 1998-04-20 PA PA19988450401A patent/PA8450401A1/es unknown
- 1998-04-22 TN TNTNSN98053A patent/TNSN98053A1/fr unknown
- 1998-04-22 DZ DZ980076A patent/DZ2465A1/xx active
- 1998-04-22 MA MA25040A patent/MA24529A1/fr unknown
- 1998-04-23 CO CO98022516A patent/CO4940472A1/es unknown
- 1998-04-23 AR ARP980101889A patent/AR015595A1/es unknown
- 1998-04-23 AP APAP/P/1998/001228A patent/AP1002A/en active
- 1998-04-24 HR HR980222A patent/HRP980222B1/xx not_active IP Right Cessation
- 1998-04-24 PE PE1998000312A patent/PE68699A1/es not_active Application Discontinuation
1999
- 1999-09-28 IS IS5200A patent/IS5200A/is unknown
- 1999-10-07 IL IL132276A patent/IL132276A/en not_active IP Right Cessation
- 1999-10-22 OA OA9900234A patent/OA11168A/en unknown
- 1999-10-22 BG BG103828A patent/BG103828A/xx unknown
- 1999-10-25 NO NO19995211A patent/NO314585B1/no not_active IP Right Cessation
2003
- 2003-08-28 IL IL157647A patent/IL157647A/en not_active IP Right Cessation
- 2003-08-28 IL IL157645A patent/IL157645A/en not_active IP Right Cessation
- 2003-08-28 IL IL157646A patent/IL157646A/en not_active IP Right Cessation
2004
- 2004-03-03 JP JP2004059879A patent/JP4036836B2/ja not_active Expired - Fee Related
- 2004-03-23 US US10/808,027 patent/US6916927B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US20040180944A1 (en)	2004-09-16
CA2288910A1 (en)	1998-11-05
CN1281588C (zh)	2006-10-25
HRP980222B1 (en)	2003-12-31
JP4036836B2 (ja)	2008-01-23
IL132276A (en)	2006-06-11
EA004315B1 (ru)	2004-02-26
RS50118B (sr)	2009-03-25
US6723719B1 (en)	2004-04-20
WO1998049166A1 (en)	1998-11-05
TNSN98053A1 (fr)	2005-03-15
PL336586A1 (en)	2000-07-03
AP9801228A0 (en)	1998-06-30
DZ2465A1 (fr)	2003-01-18
CA2288910C (en)	2003-06-24
AR015595A1 (es)	2001-05-16
JP3563078B2 (ja)	2004-09-08
SK144699A3 (en)	2001-03-12
MA24529A1 (fr)	1998-12-31
KR20010020285A (ko)	2001-03-15
JP2000510485A (ja)	2000-08-15
BG103828A (en)	2000-06-30
CZ376799A3 (cs)	2000-04-12
EP0977756A1 (en)	2000-02-09
BR9810233A (pt)	2000-10-17
IL157647A (en)	2007-05-15
ID22834A (id)	1999-12-09
AU730670B2 (en)	2001-03-08
EA200100504A1 (ru)	2002-02-28
NZ338075A (en)	2000-10-27
NO995211D0 (no)	1999-10-25
AP1002A (en)	2001-08-14
NO995211L (no)	1999-10-25
CN1188415C (zh)	2005-02-09
CO4940472A1 (es)	2000-07-24
HK1027808A1 (en)	2001-01-23
PA8450401A1 (es)	2000-05-24
SK285991B6 (sk)	2008-01-07
PE68699A1 (es)	1999-07-10
IL132276A0 (en)	2001-03-19
EA002057B1 (ru)	2001-12-24
IL157645A (en)	2007-03-08
KR100441229B1 (ko)	2004-07-22
US6916927B2 (en)	2005-07-12
JP2004196820A (ja)	2004-07-15
CZ299633B6 (cs)	2008-09-24
HRP980222A2 (en)	1999-02-28
CN1253561A (zh)	2000-05-17
TR199902646T2 (xx)	2000-05-22
EA199900866A1 (ru)	2000-04-24
YU52499A (is)	2002-08-12
OA11168A (en)	2003-04-28
NO314585B1 (no)	2003-04-14
IL157646A (en)	2006-12-10
KR100390612B1 (ko)	2003-07-07
AU7644598A (en)	1998-11-24
CN1626516A (zh)	2005-06-15

Publication	Publication Date	Title
PL336586A1 (en)	2000-07-03	Pyrazoylpyrimidinones inhibiting the cyclic guanosine 3',5'-monophosphate phosphodiesterase of type 5 (cgmp pde5) for treating sexual disorders
IS5113A (is)	1999-07-12	Notkun antagónista CB1-viðtaka til meðhöndlunar löngunartruflana
DK1047428T3 (da)	2007-10-08	Anvendelse af morpholinol til behandlingen af seksualforstyrrelser
DK0751129T6 (da)	2020-05-25	Substituerede dihydrodibenzo(b,f)azepiner, fremgangsmåde til fremstilling deraf, deres anvendelse i behandlingen af nogle lidelser i centralnervesystemet og farmaceutiske sammensætninger indeholdende disse
IS5085A (is)	1999-12-23	Nefholssamsetningar til meðhöndlunar á kynferðistruflunum
ZA989667B (en)	2000-04-25	The use of MMP-13 selective inhibitors for the treatment of osteoarthritis and other MMP-mediated disorders.
DK0861081T3 (da)	2002-05-27	Anvendelse af epinastin til behandling af smerter
EP1569652A4 (en)	2008-07-02	NUCLEOSIDES N SP 4 / SP-ACYLCYTOSINES FOR THE TREATMENT OF VIRAL INFECTIONS
FR2759581B1 (fr)	2001-01-26	Dispositif de traitement, notamment par moxa, de type acupressure
TR199801367A3 (tr)	1999-02-22	5H- tiazol (3,2-a) pirimidin türevleri
PL339425A1 (en)	2000-12-18	Treatment of behavioural disorders
DK1063990T3 (da)	2007-05-21	Anvendelse af Biochanin-beriget ekstrakt til behandling af östrogen-associerede lidelser
ID27820A (id)	2001-04-26	APLIKASI-APLIKASI PENGOBATAN POLIPEPTIDA MATURE FLINT (mFLINT) ATAU OPG3, BAGIAN KELOMPOK SUPER RESEPTOR TNF
ZA9811507B (en)	2000-06-19	Combination effective for the treatment of impotence.
IL153236A0 (en)	2003-07-06	The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
DK1105390T3 (da)	2003-09-22	Imidazo(1,2a)pyridinderivater til behandling af gastrointestinale sygdomme
DK1041985T3 (da)	2006-06-19	Kombination af benzocycloheptapyridinforbindelser og antineoplastiske lægemidler til behandling af profilerative sygdomme
ID23528A (id)	2000-04-27	Pengobatan terapeutik untuk gangguan kulit
IT1290781B1 (it)	1998-12-10	Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
IT1303677B1 (it)	2001-02-23	Dispositivo per il trattamento termico di pezzi.
EE200000391A (et)	2002-02-15	Triasiiniühendid kesknärvisüsteemihäirete raviks
DE69735417D1 (de)	2006-05-04	2,5-dihydroxybenzylsulfonderivate zur behandlung von sexuellen störungen
DK0935598T3 (da)	2004-03-29	5-heteroatom-alkylsubstituerede 3-oxopyrido(1,2-a)benzimidazol-4-carboxamidderivater egnede til behandling af sygdomme i centralnervesystemet
ZA985818B (en)	2000-01-10	Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders.
MXPA03004190A (es)	2003-09-22	Tratamiento de trastornos de ansiedad.